Balrampur Chini Mills shares rally 4% as company receives Rs 75 crore BioE3 grant from government

According to a filing with the exchange, this was awarded by the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology (DBT), Government of India, for establishing a 100 TPA PLA CoPolymer R&D Facility under the Government’s flagship BioE3 (Biotechnology for Economy, Environment & Employment) initiative.

Also Read | Balrampur Chini gets government grant for biopolymer R&D facility

The grant will accelerate the development of advanced biobased materials, strengthen India’s indigenous biomanufacturing capabilities and reinforce the country’s ambition to emerge as a global bioeconomy powerhouse.

The pilot-scale R&D facility will be established at BCML’s integrated manufacturing complex in Kumbhi, Uttar Pradesh, where the company is also setting up India’s first integrated commercial PLA manufacturing facility.

Live Events

The new facility will serve as the innovation engine for developing next-generation PLA grades and Co-polymers, enabling rapid product development, technology indigenisation, customer validation and seamless scale-up to commercial production.
The facility will develop specialised PLA grades and advanced PLA co-polymers for high-value applications. It will generate techno-economic data and process know-how for commercial-scale manufacturing. This facility will train highly skilled talent for India’s emerging biomanufacturing sector and enable collaboration with industry and research institutions to accelerate innovation in sustainable materials.Designed to bridge the gap between laboratory research and commercial manufacturing, the facility will support every stage of product development from understanding customer requirements and developing new PLA formulations to producing pilot samples, validating product performance and preparing successful technologies for commercial-scale manufacturing.

It will also create opportunities for collaboration with academia and research institutions through a limited-service model, helping strengthen India’s biotechnology innovation ecosystem.

“The Government of India’s support through this ₹75 crore BioE3 grant is a strong endorsement of the strategic role that advanced biomanufacturing will play in India’s future. This facility will help build indigenous technology, develop next-generation bio-based materials and create the scientific and technical capabilities required for India to lead the global transition towards sustainable manufacturing,” said Avantika Saraogi, Executive Director, Balrampur Chini Mills.

“We are grateful to the Department of Biotechnology and BIRAC for their confidence in our vision and look forward to contributing to India’s emergence as a global bioeconomy powerhouse,” Saraogi further said.

Also Read | PB Fintech shares in focus after massive 36% crash in a single day. Here’s why Jefferies cut target price

As countries around the world increasingly adopt bio-based materials and circular manufacturing practices, BCML’s PLA Co-Polymer R&D Facility is expected to play an important role in strengthening India’s innovation ecosystem, accelerating the commercialisation of advanced biopolymers and positioning the country as a global hub for sustainable materials.

Balrampur Chini Mills share price performance

Over the past month, Balrampur Chini Mills shares have gained 1.37% and nearly 54.52% so far this calendar year. Over the past year, the stock has rallied 42.99%, while it has gained nearly 53.83% over the past three years and 88.18% over the past five years.

Disclosure: This article has been written by Surbhi Khanna, who is not a SEBI-registered Research Analyst or an investment advisor. Surbhi Khanna does not hold any financial interest in Economic Times as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of the EconomicTimes Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment.